Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-In-Human, Open-Label, Multicenter, Multicohort Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma

NCT04712864 is registered in ClinicalTrials.gov with Legend Biotech USA Inc as lead sponsor.

NCT NCT04712864
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04712864 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-In-Human, Open-Label, Multicenter, Multicohort Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma
Lead sponsor
Legend Biotech USA Inc
Phase
Phase 1
Overall status
Unknown status
Start date
September 13, 2021
Completion date
December 31, 2025
Enrollment
50 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous t-cell lymphoma recurrent, cutaneous t-cell lymphoma refractory, peripheral t-cell lymphoma recurrent, peripheral t-cell lymphoma refractory, t-cell lymphoma